Background/Objectives: Managing cancer-related pain presents complex challenges involving the interplay between analgesic efficacy, immune system responses, and patient outcomes.Methods: Following the Scale for the Assessment of Narrative Review Articles (SANRA) criteria, we conducted a comprehensive literature search in Medline, Scopus, and Web of Science databases. The review synthesized evidence regarding opioid pain management modalities, genetic variations affecting pain perception, and associated drug metabolism.Results:The literature reveals significant associations between opioid administration and immune function, with potential implications for cancer progression and survival. Genetic polymorphisms in key genes influence individual responses to pain opioid metabolism and, finally, pain management strategies. The immunosuppressive effects of opioids emerge as a critical consideration in cancer pain management, potentially influencing disease progression and treatment outcomes.Conclusions:Genetic variants influence analgesic efficacy, while the interaction between opioid-induced immunosuppression and genetic factors impacts both pain control and survival outcomes. This emphasizes the need for personalized treatment approaches considering individual genetic profiles and immune function.
背景/目的：癌症相关疼痛的管理涉及镇痛效果、免疫系统反应及患者预后之间复杂的相互作用，面临诸多挑战。 方法：依据叙事性综述评估量表（SANRA）标准，我们在Medline、Scopus和Web of Science数据库进行了全面的文献检索。本综述综合了关于阿片类药物疼痛管理模式、影响疼痛感知的遗传变异及相关药物代谢的证据。 结果：文献显示阿片类药物使用与免疫功能存在显著关联，可能对癌症进展和生存产生影响。关键基因的遗传多态性影响个体对疼痛、阿片类药物代谢的反应，并最终影响疼痛管理策略。阿片类药物的免疫抑制作用成为癌症疼痛管理中的重要考量因素，可能影响疾病进展和治疗效果。 结论：遗传变异影响镇痛效果，而阿片类药物诱导的免疫抑制与遗传因素之间的相互作用对疼痛控制和生存结局均产生影响。这强调了个体化治疗策略的必要性，需综合考虑患者的遗传特征和免疫功能。
肿瘤(癌症)患者之家